ibritumomab tiuxetan (zevalin) Report issue

Biologics mAb ADC Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Ibritumomab tiuxetan, sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for non-Hodgkin's lymphoma. The drug uses the monoclonal mouse IgG1 antibody ibritumomab in conjunction with the chelator tiuxetan, to which a radioactive isotope is added. Tiuxetan is a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl group.   Wikipedia

  • Mechanisms of Action:
  • Multi-specific: No
  • Payload: 90-Yttrium
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No
111in ibritumomab | 111in ibritumomab tiuxetan | 90y ibritumomab tiuxetan | 90y-ibritumomab tiuxetan | 90y zevalin | 90y-zevalin | bay-86-5128 | ibritumomab | ibritumomab tiuxetan | ibritumomab tiuxetan (90y) | idec-129 | idec-in2b8 | idec-y2b8 | idec-y2b8 idec-129 | in111 ibritumomab tiuxetan | in111-ibritumomab tiuxetan | mab murine (igg1) anti p19437 (cd20_mouse) | y90 ibritumomab | y90 ibritumomab tiuxetan | yttrium-90 ibritumomab tiuxetan | yttrium-90-ibritumomab tiuxetan | yttrium y 90 ibritumomab tiuxetan | zevalin | zevalin kit-indium-111 | zevalline

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue